Tel Aviv-based NeuroAI company Hemispheric has officially emerged from stealth, securing an impressive $52 million in funding to advance its brain decoding technology. The company is building a foundational AI platform designed to measure and understand the complexities of the human brain. Co-founded by computational neuroscientist Dr. Hagai Lalazar and FaceID co-inventor Gidi Littwin, Hemispheric is poised to revolutionize mental healthcare.
A New Frontier in Brain Health
The company's core offering is the Descartes platform, a system designed for accessibility and ease of use. Patients simply wear a lightweight, dry EEG headset for fifteen minutes while engaging with an application on a standard tablet or phone. This streamlined process captures crucial brain activity without requiring surgery or complex, lengthy protocols for data collection.
At the heart of the platform is Descartes, a frontier AI model trained on an extensive and proprietary large-scale EEG dataset. This advanced model translates raw brainwave data into clear, actionable understanding for clinicians and researchers. The technology provides objective results that can significantly enhance diagnostic accuracy and treatment monitoring for various neurological conditions.
Strategic Investment and Vision
The significant $52 million investment was supported by a diverse group of prominent backers, including Hanaco Ventures, OneMind/Awareness Capital, and L Catterton. This substantial financial endorsement highlights the investment community's strong confidence in Hemispheric's innovative approach and its potential market impact. The funding provides the necessary resources for the company to scale its operations and accelerate its mission.
Hemispheric has outlined a clear strategy for deploying the new capital to fuel its next phase of growth. The company intends to expand the use of its Descartes platform with government, healthcare, and pharmaceutical partners. Key priorities also include growing its global brain data network, advancing regulatory pathways, and scaling its U.S. team.
Addressing Critical Mental Health Challenges
The platform is initially focused on improving outcomes for some of the most challenging brain health conditions. These include post-traumatic stress disorder (PTSD), mild traumatic brain injury (mTBI), depression, anxiety, schizophrenia, and Alzheimer’s disease. Hemispheric provides clinicians with a powerful tool for precise diagnosis and for selecting the most effective patient-specific interventions.
Beyond immediate diagnostics, the company's ultimate ambition is to fundamentally extend human mental health span by several decades. This long-term vision is centered on creating a new standard for objective brain measurement and understanding. By decoding the brain, Hemispheric aims to shift healthcare from reactive treatment to proactive brain health management.
The Leadership Behind the Innovation
The company's leadership combines deep scientific knowledge with proven technological expertise, a key factor in its early success. Co-founder Dr. Hagai Lalazar is a respected computational neuroscientist, providing the core scientific direction for the platform. His partner, Gidi Littwin, brings invaluable experience from co-founding RealFace, which was acquired by Apple, and co-inventing FaceID.
With its successful $52 million funding round and pioneering technology, Hemispheric is strongly positioned to become a leader in the NeuroAI field. The company's non-invasive Descartes platform promises to transform how we diagnose, treat, and monitor brain health conditions. As it expands globally, Hemispheric's work could usher in a new era of precision medicine for mental and neurological wellness.